RESEARCH ARTICLE

Hepatic Proliferation and Angiogenesis Markers Are Increased after Portal Deprivation in Rats: A Study of Molecular, Histological and Radiological Changes

Florent Guérin1,2,3*, Mathilde Wagner2,4*, Antoine Liné2,3, Magaly Zappa2,4, Magali Fasseu2, Valérie Paradis2,5, Valérie Vilgrain2,4, Bernard E. Van Beers2,4, Josette Legagneux3, Richard Moreau2,6, Philippe Lettéron2

1 Department of Pediatric Surgery, Hôpitaux Universitaires Paris-Sud (Bicêtre), Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Sud-Paris11, Le Kremlin Bicêtre, France, 2 Institut National de la Santé et de la Recherche Médicale (INSERM): Unité Mixte de Recherche (UMR) 1149, Centre de Recherche sur l’Inflammation, Faculté de Médecine Xavier Bichat, Université Denis Diderot-Paris 7, Paris, France, 3 Laboratoire de Microchirurgie, Agence Générale des Equipements et Produits de Santé (AGEPS), Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France, 4 Department of Radiology, Hôpitaux Universitaires Paris Nord Val de Seine (Beaujon), Assistance Publique Hôpitaux de Paris (AP-HP), Université Denis Diderot-Paris 7, Clichy, France, 5 Department of Pathology, Hôpitaux Universitaires Paris-Nord-Val-de-Seine (Beaujon), Assistance Publique Hôpitaux de Paris (AP-HP), Université Denis Diderot-Paris 7, Clichy, France, 6 Department of Hepatology, Hôpitaux Universitaires Paris-Nord-Val-de-Seine (Beaujon), Assistance Publique Hôpitaux de Paris (AP-HP), Université Denis Diderot-Paris 7, Clichy, France

* These authors contributed equally to this work.

florent.guerin@bct.aphp.fr

Abstract

Background & Aims

To determine the pathogenesis of liver nodules, and lesions similar to obliterative portal venopathy, observed after portosystemic shunts or portal vein thrombosis in humans.

Methods

We conducted an experimental study comparing portacaval shunt (PCS), total portal vein ligation (PVL), and sham (S) operated rats. Each group were either sacrificed at 6 weeks (early) or 6 months (late). Arterial liver perfusion was studied in vivo using CT, and histopathological changes were noted. Liver mRNA levels were quantified by RT-QPCR for markers of inflammation (IL10, TNFA), proliferation (IL6ST, MKI67, HGF, HNF4A), angiogenesis: (VEGFA, VEGFR 1, 2 and 3; PGF), oxidative stress (NOS2 and 3, HIF1A), and fibrosis (TGFbeta). PCS and PVL were compared to the S group.

Results

Periportal fibrosis and arterial proliferation was observed in late PCS and PVL groups. CT imaging demonstrated increased arterial liver perfusion in the PCS group. RT-QPCR showed increased inflammatory markers in PCS and PVL early groups. TNFA and IL10 were
increased in PCS and PVL late groups respectively. All proliferative markers increased in the PCS, and \textit{Hnf4a} in the PVL early groups. \textit{Mki67} and \textit{Hnf4a} were increased in the PCS late group. \textit{Nos3} was increased in the early and late PCS groups, and \textit{Hif1a} was decreased in the PVL groups. Markers of angiogenesis were all increased in the early PCS group, and \textit{Vegfr3} and \textit{Pgf} in the late PCS group. Only \textit{Vegfr3} was increased in the PVL groups. \textit{Tgf} was increased in the PCS groups.

\textbf{Conclusions}

Portal deprivation in rats induces a sustained increase in intrahepatic markers of inflammation, angiogenesis, proliferation, and fibrosis.

\textbf{Introduction}

Various liver nodules and intrahepatic pathological changes have been observed in the human liver after both surgical and congenital portosystemic shunts, as well as extrahepatic portal vein thrombosis. These include benign liver tumours such as focal nodular hyperplasia and liver cell adenoma, and malignant tumours such as hepatocellular carcinoma and hepatoblastoma [1-4]. Commonly, quiescent histopathological periportal changes with similar appearances to obliterator of portal venopathy have been observed, including paucity of the portal vein, perisinusoidal fibrosis, ductal proliferation, and an increase in the number of capillaries or arterioles in the portal space [2, 3, 5]. These changes have also been observed in animals with congenital or acquired portacaval shunt (PCS) [6, 7]. However, only one study has demonstrated liver nodules after PCS in rats, [8].

Recent experimental studies have focused on the metabolic and inflammatory changes following PCS in rats [9-11]. These studies however, focused on the extrahepatic expression of inflammatory molecules and liver atrophy, rather than intrahepatic changes. Currently, little is known regarding the intrahepatic expression of growth factors and markers of inflammation, angiogenesis, and fibrosis in the liver, following portal vein thrombosis or PCS. Expression of these growth factors might explain the paradox between liver atrophy, periportal vasculogenesis and fibrosis, and the abnormally high occurrence of nodules in humans.

The aim of this study was to assess the morphologic changes (radiological and histopathological), and the expression of markers of inflammation, angiogenesis and fibrosis in the liver, following experimental portal vein deprivation.

\textbf{Materials and Methods}

\textbf{Animals}

Experiments were conducted in 200–260g 6 week-old male Wistar rats: \textit{ratus norvegicus} (Laboratoire Janvier, France). The experimental procedures used in this study complied with the principles and practices of the Ethical Guidelines from European Community Council Directive (2010/63/EU). Details of this study were approved by the local Bichat-Debré Ethics Committee in accordance with the French law for the protection of animals.

The condition of the animals was checked twice daily, and once daily over the week-end and bank holidays. Humane endpoints used for this experiment were based on clinical symptoms: no return to normal activity 48 hours after the procedure, lack of activity, aggressive behaviour, weight loss, and loss of appetite. If any of these endpoints were reached, analgesia with
Buprenorphine (0.05mg/Kg/8h) was started followed, by planned euthanasia using Isoflurane overdose (10% 4l/min).

**Experimental design**

The animals were divided (randomised block design) into three groups: rats with end-to-side portacaval shunt (PCS), complete portal vein ligation (PVL), and sham-operated rats (S). Each group was divided into two subgroups, early (6 weeks post-operatively) and late (6 months post-operatively) sacrifice groups. The initial study was designed with 13 animals in each early and late PCS and PVL group, expecting an arbitrary mortality rate of 20% in these groups, and 12 in each S group for an expected mortality rate of 10% in the S group. These expected mortality rate were approved by our institutional ethics committee. There were 9/26 (i.e. 34% CI [17–55]) deaths in the PCS groups, 7/26 (i.e. 27% CI [11–47]) in the PVL group, and 2/24 (i.e. 8% CI [1–27]) in the S group. The number of remaining animals in each group and subgroup is displayed in Table 1.

**Surgical Procedures**

The rats were anaesthetized with Isoflurane (2%, 2l/min). Intra-operative and post-operative analgesia was achieved with a subcutaneous injection of buprenorphine (0.05 mg/kg/8h for 48 hours). All groups had the same first steps of the procedure. With an operating microscope (OPMI-1FR, Carl Zeiss; Oberkochen, Germany) a median laparotomy was performed, and the intestines were retracted to expose the inferior vena cava and the portal vein. The end-to-side PCS was performed according to the technique previously described by Lee [12]. As the rats do not tolerate one-step total PVL, we performed the two-step procedure as described by Koshy [13]. After clamping the inferior vena cava (IVC) to reproduce the same condition as for the PCS, a 21 gauge metallic stent was placed along the portal trunk and stitched around the portal vein with 7/0 silk sutures. The stent was removed 30 minutes later, as well as the IVC clamp, producing portal stenosis. The second step consisted of a second laparotomy 48 hours later. The stenosed portal trunk was tied off to complete a portal vein ligation. The PVL and S groups underwent a general anaesthetic during the same period to expose them to the same amount of anaesthetics, thereby avoiding bias in our analysis.

Sham operated rats had both IVC and portal vein clamped for the same duration as the PCS and PVL groups. All the clamps were released after 30 minutes, and the abdominal wall was closed. The animals were recovered for 6 hours before returning to a normal diet and housing.

**Imaging**

In-vivo perfusion computed tomography (CT) scans were performed before sacrifice. Following an intra-muscular anaesthetic using ketamine (35 mg/kg) and xylazine (7 mg/kg), a polyurethane catheter was placed in the femoral vein. A CT-scan was performed (VCT 64, General Electric, Milwaukee, WI, USA), using the following parameters: 80 kV, 160 mA, Field of view: 15 cm. Initially, an abdominal CT without contrast was performed. Subsequently, 0.1ml/100g of an iodinated contrast agent (Visipaque, 270mg/ml, GE Healthcare, Ireland) was manually injected into the femoral vein, followed by a saline flush.

**Table 1. Distribution of the remaining rats, available for experiments between PCS, PVL, and S groups in early and late sub-groups.**

|       | PCS | PVL | S |
|-------|-----|-----|---|
| Early | 9   | 13  | 12|
| Late  | 8   | 6   | 10|

doi:10.1371/journal.pone.0125493.t001
injected, and 4 CT slices (thickness = 5 mm) centred on the liver hilum were acquired every 0.5 seconds over 1 minute, and every 4 seconds for 4 subsequent minutes.

Radiological analysis: the CT images were transferred to a workstation (Advantage Windows, GE Healthcare, Buc, France) for perfusion analysis by a radiologist (MW). Two vascular regions of interest (ROI) were drawn: one in the aorta, and one in the portal vein for the S group, and in the largest collateral vessel in the PVL group. In the PCS group, a ROI was placed in the paravertebral muscle, as there was no portal blood flow. In all rats, a parenchymal ROI was located in the right median lobe of the liver, avoiding the large vessels (Fig 1). CT attenuation curves were used to calculate the blood perfusion (ml/min/100ml), blood volume (ml/100ml), and the arterial fraction (%) using the Johnson-Wilson distributed model [14] with the GE CT perfusion 4D software (General Electrics Healthcare, CT, USA). Total blood flow (ml/min) was calculated as blood perfusion times liver volume.

Histological and molecular analysis

All animals were sacrificed following CT examination during the same anaesthesia. They were weighed before a midline abdominal incision was made, with subsequent exsanguination via the IVC. The liver was removed and weighed. The liver/animal weight ratio was calculated.

Samples of the right, middle and left lobes of the liver were stored in 10% formalin for standard histopathological studies with hematoxylin-eosin-safran staining. A qualitative analysis of the portal spaces was performed.

For molecular analysis, 50mg of each lobe were rapidly frozen in acetone, chilled with dry ice and stored at -80°C for messenger ribonucleic acid (mRNA) quantification by reverse transcriptase polymerase chain reaction amplification (RT-PCR). Total RNA was extracted from cells using Trizol reagent (Invitrogen, Cergy-Pontoise, France). The quality and integrity of RNA was evaluated using an Agilent 2100 bioanalyser (Agilent Technologies, Inc. Santa Clara, CA). One μg of total RNA was incubated in genomic Deoxyribonucleic acid (gDNA) Wipeout Buffer at 42°C for 2 minutes for gDNA contamination. After gDNA elimination, the RNA sample was ready for reverse transcription using a master mix prepared from Quantitect reverse transcription (Qiagen, Courtaboeuf, France). The differential expression of cytokine genes was assessed by real time quantitative polymerase chain reaction (RT-qPCR) using the SYBR Green based detection system on LightCycler 480 (Roche Diagnostics, Mannheim, Germany). Gapdh was used as housekeeping gene. The analysis of relative change in mRNA expression of target gene was based on 2-delta-delta-Ct method, therefore both PCS and PVL groups were compared to the value of the Sham which was 1, [15]. Genes of interest, displayed with their primers in Table 2, were classified as inflammation, proliferation, cell oxidative stress, angiogenesis, and fibrosis genes.

Western blots were used to measure the protein expression of Hif1a in the liver.

In tissue samples (50–60 mg), nuclear and cytoplasmic fraction protein concentrations were determined by the BCA assay. Total protein equivalents (50 μg) for each sample were separated by NuPAGE 4–12% tris gel (life technologies, Ca, USA) and were transferred onto nitrocellulose membrane. The membrane was immediately placed into blocking buffer containing 5% non-fat milk in TBS and 0.01% Tween-20 at 20°C for 1 h. The membrane was incubated with rabbit polyclonal Hif1a (1:1000) overnight at 4°C, followed by incubation in an anti-rabbit IgG-horseradish peroxidase conjugated antibody (1:10 000). The membranes were incubated with ECL plus detection reagents (Amersham LifeScienceInc, Buckinghamshire, UK), exposed to FUSION-FX Chemiluminescence System (BioRad, Nanterre, France). Pre-stained protein markers were used for molecular weight determinations.
Statistics

Statistical analysis was performed using GraphPad Prism software (Graphpad Inc., Ca, USA). The results were expressed as median and range. The 3 groups were analysed using Kruskal-Wallis or Mann Whitney tests with Dunn’s multiple comparison test. Correlations were performed using the Spearman test. Results were considered significant when $P < 0.05$.

Results

Early sacrifice group (6 weeks)

Mortality: There were 4 deaths in the early PCS group (1 intra-operative cardiac arrest during the clamping procedure, 1 during the CT scan secondary to bleeding at the catheter insertion site, and 2 late sudden deaths of unknown cause (at 4 and 5 weeks following the procedure), despite daily check of humane endpoints, and post mortem examination demonstrating no evidence of shunt thrombosis.

The liver-weight ratio was significantly lower in the PCS group (2.21% [2.11–2.37]) than in PVL (3.33% [3.17–3.40] (P < 0.001)) and S groups (3.45% [3.29–3.67] (P < 0.001)).

Table 2. Gene, protein and the corresponding primers used for RT-QPCR studies.

| Category       | Gene        | Encoded protein                                      | Upper primer                                      | Lower primer                                      |
|----------------|-------------|------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Inflammation   | Tnf, Tnfa   | Tumour necrosis factor                               | 5’GCCAGGAGGATGC ATGCTT CTTTTC 3’                  | 5’CCATGGAGGTTG GAGGTTG CTACAG3’                   |
| Inflammation   | Il10        | Interleukin 10                                       | 5’GGC GCT GCT ATG CAT TTTTTC 3’                   | 5’AGA TGC CTT CTT CTT GGA GCT TAT T 3’           |
| Proliferation  | Hgf         | Hepatocyte growth factor                             | 5’TGTCTTCTGTC TTGCAAGGA3’                         | 5’TCCGTCTTTGGATATTGC3’                           |
| Proliferation  | Il6st       | Interleukin-6 signal transducer                      | 5’GCACAGACTATGGCTTCCATT 3’                        | 5’CACAGAAGAGGTTGGAAGG3’                          |
| Proliferation  | Mki67       | Antigen KI-67                                        | 5’TCACCTGTTCTGGTACCTGTTT3’                        | 5’GGCCAAAGAGATGCAAAA3’                           |
| Proliferation  | Wnt2        | Wingless-type MMTV integration site family member 2  | 5’GGGAAAGTCAAGTGGCAACA3’                          | 5’GAAGCCCGAGAAAAATGGCA3’                         |
| Proliferation  | Hnf4a       | Hepatocyte nuclear factor 4-alpha                    | 5’CGGCTCCCTGTGAACCTTCTT3’                         | 5’GACAGACAGACACACCTTGA3’                         |
| Cellular stress| Nos2        | Nitric oxide synthase. inductible                    | 5’GAAGAGGGAGCTGTTGTAGG3’                          | 5’AGCATGGAGCTCGTGAGTTC3’                         |
| Cellular stress| Nos3        | Nitric oxide synthase.endothelial                   | 5’GAGGGGAGCGCTGTTGTAGG3’                          | 5’AGCATGGAGCCCTTGATGG3’                          |
| Cellular stress| Hlf1a       | Hypoxia inducible factor 1, alpha subunit            | 5’GCAACGTGGAAGGTGCTG 3’                           | 5’CGTACAGGCGGTTTCTTGTAG3’                        |
| Angiogenesis   | Vegfa       | vascular endothelial factor A                        | 5’GACGTCCATGAACTCAGCA3’                           | 5’GTACCTCCAGCAGGCAAGT3’                          |
| Angiogenesis   | Fit1        | Vascular endothelial growth factor receptor 1        | 5’TGGTCCTCAGTCCAGGTGA3’                           | 5’GAGGAGCTTCCACAAATGC3’                          |
| Angiogenesis   | Kdr         | kinase insert domain protein receptor Vascular endothelial growth factor receptor 2 | 5’CGGCTTCTGTGAACCTTCTT3’                         | 5’GAGCACGACATCCTGTGAAC3’                         |
| Angiogenesis   | Fit4        | Fms-related tyrosine kinase 4 Vascular endothelial growth factor receptor 3 | 5’GCCAGTCACTGGCTTCTGT3’                         | 5’AAAGCCTCCTTCAGGTGAGC3’                         |
| Angiogenesis   | Pgf         | Placenta growth factor                               | 5’TCTCTTCTCCTGTGGTTT3’                           | 5’GGGATCCACATCCTCAGGT3’                          |
| Fibrosis       | Tgb         | Transforming growth factor beta-1                    | 5’ACTTCCAACCCAGGTCTTTC3’                          | 5’GGGAGGCGCTTGATACCAAC3’                         |
|                | Tgb1        | Transforming growth factor beta-1                    |                                                   |                                                   |

doi:10.1371/journal.pone.0125493.g001
no statistical difference between PVL and S (P = 0.089). Histopathological features in the liver were similar in PCS and PVL, with no changes in the S group.

CT demonstrated the development of a portal cavernoma in all rats in the PVL group (13/13), enabling identification of the portal ROI in the largest collateral vessel (Fig 1). Arterial fraction was 0.86 [0.46–1] in the PCS group, 0.30 [0.04–0.71] in the PVL group, and 0.26 [0.04–0.54] in the S group. The arterial fraction was significantly higher in the PCS than in the S group (P = 0.016), but did not differ significantly between the PVL and S groups (P = 0.151). Blood perfusion and total blood flow did not differ significantly between the three groups (P = 0.181 and P = 0.145, respectively) (Fig 2).

Molecular studies using RT-QPCR showed a significant increase of Tnfa in both PCS and PVL, compared to S (respectively P = 0.010 and P < 0.003). This was counterbalanced by an increase in the anti-inflammatory molecule Il10 in both PCS and PVL compared to S (respectively P = 0.023; P = 0.001). The proliferative markers Hgf, Il6st, Mki67, Hnf4a were increased in the PCS group compared to the S group (P = 0.034; P = 0.023; P = 0.015; and P = 0.003), whereas only Hnf4a was significantly increased in the PVL group (P = 0.044). Wnt2 was significantly decreased compared to S group both in the PCS group (P = 0.015), but not in the PVL group (P = 0.269). The cellular stress marker Nos3 was increased only in the PCS group (P = 0.015) but not in the PVL group (P = 0.313). Hif1a was not elevated in the PCS group, but significantly decreased in the PVL group (P = 0.03). Angiogenesis markers Vegfa, Flt1 (VEGFR-1), Kdr (Vegfr-2) Flt4 (Vegfr3); and Pgf were significantly increased in the PCS group, compared to the S group P = 0.015; P = 0.003, P = 0.015; P = 0.003, and P = 0.015 respectively, whereas only Flt4 was increased in the PVL group (P = 0.042). Fibrosis marker Tgfb was increased only in the PCS group (P < 0.003); (Fig 3).

Late sacrifice group (6 months)

Mortality: There were 5 deaths in the late PCS group (2 intra-operative cardiac arrests during clamping, 3 late sudden deaths of unknown cause (at 5, 9 and 12 weeks post-procedure without evidence of shunt thrombosis on post mortem examination). There were 7 deaths in the late PVL group (2 intra-operative cardiac arrests, 1 during CT scanning, 1 secondary to bleeding from the catheter insertion site, and 3 late sudden deaths of unknown cause (at 6, 7, 13 weeks post procedure despite no evidence of shunt thrombosis on post-mortem examination), and 2 late sudden deaths of unknown cause in the S group (4 and 7 weeks post-procedure), despite no evidence of shunt thrombosis on post mortem examination.

All the late deaths in this study were not detected by the humane endpoints methods. The liver weight ratio was significantly lower in the PCS group: 2.11% [2.00–2.31] than in the PVL group 2.46% [2.35–2.72] (P = 0.004), and the S group 2.73% [2.62–3.00] (P < 0.001).

Histopathological changes observed included periportal fibrosis, and ductal and capillary proliferation, with more than two arteries in more than 30% of portal spaces for PCS and PVL. The only difference between PCS and PVL was portal vein congestion in the PVL group (Fig 4). These changes were similar to the observed portal space changes following portacaval shunts in humans [2].

On Fig 4A, there are multiples arteries (stars) with ductular proliferation (white arrowheads), and fibrosis (black arrow). The same pattern with less fibrosis is seen on the liver biopsy of a rat with PVL (B). (C) shows a normal portal space on a sham rat.

As demonstrated in the early group, all the rats (6/6) in the PVL group had radiological evidence of development of a portal cavernoma (Fig 1). The arterial fraction was 0.76 [0.49–1] in PCS group, 0.37 [0.09–0.50] in the PVL group, and 0.24 [0.11–0.52] in the S group. The arterial fraction was significantly increased in the PCS compared to the S group (P < 0.001), but did
not differ significantly between the PVL and S groups (P = 0.315). Blood perfusion was the same in all three groups (P = 0.326), but total blood flow was significantly lower in both the PCS: 1.98 ml/min [0.64–5.04] and PVL group: 2.00 ml/min [0.90–2.81], than in the S group: 3.21 ml/min [1.82–5.34] (P = 0.022 and P = 0.025 respectively) (Fig 2).

Molecular studies using RT-QPCR showed a significant increase of Tnfa only in the PCS group compared to S group (P = 0.027), whereas Il10 was increased only in the PVL group (P = 0.031). Proliferative markers Mki67 and Hnf4a were increased only in the PCS group compared to the S group (P = 0.003, P = 0.003 respectively). Wnt2 was significantly decreased only in the PCS compared to the S group (P = 0.031). Nos3 remained higher in the PCS group (P = 0.023) and Hif1a significantly decreased in the PVL group (P = 0.03). Among the markers of angiogenesis, only Flt4 (Vegfr3) and Pgf remained significantly increased in the PCS group, compared to the S group (P = 0.003; P = 0.015 respectively), whereas none was increased in the PVL group. The marker of fibrosis, Tgfb, was increased only in the PCS group compared to S (P ≤ 0.003) (Fig 3).

In the early group, there was a significant correlation between the arterial fraction in the PCS and PVL group, with Hnf4a (r = 0.46, P = 0.045), and Flt4 (Vegfr3) (r = 0.69, P < 0.001). In the late group, there was a significant correlation between the arterial fraction of PCS and PVL with Hnf4a (r = 0.60; P = 0.019), Nos3 (r = 0.61; P = 0.017), Flt4 (Vegfr3) (r = 0.60; P = 0.019) and Tgfb (r = 0.53; P = 0.003).

Hif1a western blot were negative at 6 Weeks and 6 months for both PCS and PVL groups (Fig 5).

Discussion

In humans, portal deprivation resulting from PCS or portal vein thrombosis, has been observed to induce a wide spectrum of liver nodules [1–4, 16]. Portal deprivation is also known to induce fibrosis and arterial proliferation in the portal space [2, 5, 17]. The underlying mechanisms of these changes however, remain unclear. Our experimental study has demonstrated that portal deprivation in rats induces sustained intrahepatic expression of inflammatory, angiogenic, proliferative, oxidative and fibrogenic molecules, despite liver atrophy. These changes occurred with a distinct pattern of expression, depending on whether the portal flow is minimal but present (PVL), or fully diverted from the liver (PCS).

Previous experimental studies have addressed the paradox between atrophy and the regenerative pattern observed in the liver and other organs after PCS [9, 10]. Tnfa is a pro-inflammatory and Il10 an anti-inflammatory cytokine. Our results are different to those of Garcia et al. who reported no increase of Tnfa and Il10 mRNAs in the liver in PCS rats compared to their control rats at one month, [9]. In our study, there was a sustained Tnfa increase in PCS compared to S, whereas Il10 increased in the liver only in the early PCS group. We do not have a good explanation for this discrepancy apart from an earlier sacrifice time in their study (4 weeks). Our study demonstrated in both PCS and PVL groups an early, balanced pro and anti-inflammatory response, mediated by Tnfa and Il10 respectively. At 6 months, Il10 expression persisted in the PCS group, where portal inflow is patent via the cavernoma, demonstrated on
Fig 3. Results of mRNA quantification by RT-QPCR. Aligned dot plots with bars at median for the expression of inflammatory (Tnfa, Il10), proliferative (Hgf, Il6st, Mki67, Wnt2, Hnf4a), Oxidative stress (Nos2&3), angiogenetics (Vegfa, Flt1/VEGFR-1, Kdr/Vegfr2,Flt4/Vegfr3), and fibrotic (Tgfb) mRNA markers by RT-QPCR according to the Delta-Delta Method (Sham = 1) at 6 weeks and 6 months. 

PCS: Portacaval shunt. 
PVL Portal vein ligation. 
S: Sham. 
*: significant difference. 

doi:10.1371/journal.pone.0125493.g003

CT imaging. This might support the idea that portal flow in the liver has an anti-inflammatory effect. All but Wnt2 proliferative mRNA markers tested increased in the early PCS group, probably in response to injury caused by portal deprivation. The only proliferative marker found to be increased in the PVL group was Hnf4a. At 6 months, the proliferative markers Mki67 and Hnf4a were present only in the PCS group. Hnf4a is a central transcriptional regulator of hepatocyte differentiation, and is also known to attenuate hepatic fibrosis induced by portal impairment in our PCS group [18, 19]. Wnt2 which was decreased in the early and late PCS groups, is a protein which activates the beta-catenin pathway. The Wnt2/beta-catenin pathway is involved in liver organogenesis, differentiation, proliferation, but also tumorogenesis, but was never assayed in PCS models [20]. In our study, the decrease of Wnt2 expression could be the result of downregulation caused by other pathways like Hgf/c-Met.

Among the nitric oxide synthases, only the Nos3 (endothelial) was significantly increased in both early and late PCS groups. Nos3 is expressed in endothelial cells and hepatocytes, and its over expression could reflect either the protective effects due to ischaemic changes, but also hepatocyte proliferation and regeneration following chronic liver injury secondary to PCS [21]. This result is different from the study by Garcia et al. in which Nos2 (inducible) was increased in the liver without expression of Nos3 [9]. We do not have any explanation for this discrepancy, except statistical bias for Nos2 (our P value almost reached statistical significance at 6 weeks and 6 months, respectively P = 0.054 and P = 0.078). The fact that Hif1a mRNA and protein expression was not increased in the PCS groups and decreased in the PVL groups, shows that this transcriptional factor was not involved or down regulated in PCS or PVL livers. This could be related to the known interaction between Hif1a and Wnt2 in ischemia reperfusion injury repair. The difference in Hif1a mRNA expression between the PVL and PCS groups could also explain the observed difference in pro-angiogenic (Vegfa) and fibrotic markers (Tgfb) [22].

The mRNAs of vascular endothelial growth factor A and its receptors Flt1 (VEGFR-1), Kdr (Vegfr-2) and Flt4 (Vegfr3) were all increased in the early PCS group, before returning to basal levels in the late group, apart from Vegfr3. Similar results for Vegfr-2 over-expression were
Vegfr-2 is the key receptor of Vegfa and induces NO synthesis via Nos3. This could also explain why Nos3 was over-expressed in our study. However, this is not a persistent effect, and other molecules such as Pgf, secreted by sinusoidal endothelial cells to promote vasodilatation, proliferation, and fibrosis, might take over the Vegfa/Vegfr-2 pathway.

Transforming growth factor-beta (Tgfb) is the most potent hepatic profibrogenic cytokine that also exerts its biological effects on tissue and organ development, cellular proliferation, differentiation, survival and apoptosis. In our study, the increase in Tgfb expression may reflect the response to fibrosis, but also long-term hepatocyte proliferation. This may explain the occurrence of liver cell tumours in humans after PCS.

The results of the mRNA studies should be interpreted with caution, as we have not assessed most of the protein expression in liver parenchyma. In both PCS and PVL groups, we had no radiological or histopathological evidence of any liver nodules. Until now, only one previous study has reported liver nodules at 6, 12, and 18 months following PCS in rats. This observation has never subsequently been demonstrated. Our study demonstrated an increase in growth factors, proliferation and angiogenesis, which may favour the growth of a pre-existing tumour rather than driving hepatocarcinogenesis itself. In this study, imaging was used to assess the different patterns of liver perfusion in PCS, PVL, and S. In PCS, the arterial fraction increased significantly to balance the lack of portal perfusion. However, overall total blood flow decreased along with the liver weight in order to maintain a liver perfusion. Similar trends were observed in the rats with portal vein ligation at 6 months, which may be attributed to the small number of animals in this group. Increases in hepatic arterial fraction were observed to balance a decreased portal venous flow in both cirrhotic and normal livers in a study by Zipprich et al. The observed changes in liver perfusion and volume in PCS and PVL are explained by the liver arterial versus portal balance. Following total or partial portal vein obstruction, the arterial fraction of perfusion increases, as part of the hepatic artery buffer response to maintain total liver blood flow. When the hepatic artery buffer response capacity is reached, the total liver blood flow decreases and liver atrophy occurs, in order to maintain an intact blood liver perfusion. These observations were confirmed in our

Fig 5. Western blot of Hif1a protein in the liver at 6 weeks (6W) and 6 Months (6M) in Sham (S), Portacaval shunt (PCS), and Portal vein Ligation (PVL) rats. Nuclear (NUCL) and cytoplasmic (CYT) protein were fractioned and assayed for Histone 3 to serve as a nuclear marker and Actin to serve as a protein marker. There is no staining for Hif1a in each 6 weeks and 6 months groups.
study, which demonstrated a decreased liver weight ratio along with maintenance in liver perfusion quantified non-invasively using perfusion CT.

Interestingly, the increase in arterial fraction was confirmed both at a macroscopic level on histopathology specimen, and by molecular biology studies. Correlations between arterial fraction and proliferation (Hnf4a), angiogenesis (VEGFR1, Vegfr2, and 3), and Tgfb expression were observed, suggesting that perfusion CT might be useful in monitoring arterial and fibrotic changes induced by portal deprivation in the liver, at a macroscopic scale.

The role of perfusion CT in clinical practise, especially for monitoring treatment in children, is limited due to radiation exposure. Perfusion MR imaging may therefore provide an alternative.

In conclusion, this experimental study has demonstrated the long-term effect of portal deprivation on mRNA expression of proliferative and angiogenic factors in the liver, suggesting that these changes are the result of portal vein deprivation, rather than being associated with the portal vein malformation. Pharmacologic intervention with the anti-angiogenic Sorafenib has already been performed in partial PVL rats in the past [37]. This molecule could be tested in the future, in both total PVL and PCS rats, and may reveal either its positive or negative effects on the markers already tested in this present study.

Acknowledgments
We wanted to thank Miss Caroline Pardy for reviewing the English editing style of the manuscript.

Author Contributions
Conceived and designed the experiments: FG MW BVB JL RM PL. Performed the experiments: FG MW AL MZ MF VP. Analyzed the data: FG MW AL MZ MF VP VV. Contributed reagents/materials/analysis tools: PL MZ MW MF. Wrote the paper: FG MW BVB. Critically appraised the manuscript: MW AL MZ VV BVB RM PL. Supervised the experiments on the animals: JL. Supervised the study: RM.

References
1. Franchi-Abella S, Branchereau S, Lambert V, Fabre M, Steinberg C, Losay J, et al. Complications of Congenital Portosystemic Shunts in Children: Therapeutic Options and Outcomes. J Pediatr Gastroenterol Nutr 2010; 51:322–330. doi:10.1097/MPG.0b013e3181d9c9b2 PMID: 20601902
2. Guérin F, Porras J, Fabre M, Guettier C, Pariente D, Bernard O, et al. Liver nodules after portal systemic shunt surgery for extrahepatic portal vein obstruction in children. J Pediatr Surg 2009; 44:1337–1343. doi: 10.1016/j.jpedsurg.2008.11.003 PMID: 19573658
3. Lisovsky M, Konstas AA, Misdraji J. Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): A Histopathologic Evaluation. Am J Surg Pathol 2011; 35:1381–1390. doi: 10.1097/PAS.0b013e3182230ce4 PMID: 21836489
4. Barton JW 3rd, Keller MS. Liver transplantation for hepatoblastoma in a child with congenital absence of the portal vein. Pediatr Radiol 1989; 20:113–114. PMID: 25577573
5. Cazals-Hatem D, Hillaire S, Rudlier M, Plessier A, Paradis V, Condat B, et al. Obliterative portal venopathy: Portal hypertension is not always present at diagnosis. J Hepatol 2011; 54:455–461. doi: 10.1016/j.jhep.2010.07.038 PMID: 21087805
6. Lee KCL, Winstanley A, House JV, Lipscomb V, Lamb C, Gregory S, et al. Association between hepatic histopathologic lesions and clinical findings in dogs undergoing surgical attenuation of a congenital portosystemic shunt: 38 cases (2000–2004). J Am Vet Med Assoc 2011; 239:638–645. doi: 10.2460/javma.239.5.638 PMID: 21879964
7. McCuskey RS, Vonnahme FJ, Grün M. In vivo and electron microscopic observations of the hepatic microvasculature in the rat following portacaval anastomosis. Hepatology 1983; 3:96–104. PMID: 6800439
8. Weinbren K, Washington SL. Hyperplastic nodules after portacaval anastomosis in rats. Nature 1976; 264:440–442. PMID: 1004573

9. García C, Gine E, Aller MA, Revuelta E, Arias JL, Vara E, et al. Multiple organ inflammatory response to portosystemic shunt in the rat. Cytokine 2011; 56:680–687. doi: 10.1016/j.cyto.2011.08.033 PMID: 21975127

10. Gandhi CR, Murase N, Subbotin VM, Uemura T, Nalesnik M, Demetris AJ, et al. Portacaval shunt causes apoptosis and liver atrophy in rats despite increases in endogenous levels of major hepatic growth factors. J Hepatol. 2002; 37:340–348. PMID: 12175629

11. Kurinna S, Barton MC. Cascades of transcription regulation during liver regeneration. Int J Biochem Cell Biol 2011; 43:189–197. doi: 10.1016/j.biocel.2010.03.013 PMID: 21975127

12. Lee SH, Fisher B. Portacaval shunt in the rat. Surgery 1961; 50:668–672. PMID: 14463560

13. Koshy A, Cerini R, Bernuau D, Hadengue A, Girod C, Lebrec D. Model for the study of portal-systemic collateral vascular resistance in the conscious rat. J Pharmacol Methods 1988; 20:265–277. PMID: 3236796

14. Johnson JA, Wilson TA. A model for capillary exchange. Am J Physiol 1966; 210:1299–1303. PMID: 5923068

15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔC(T)) Method. Methods 2001; 25:402–408. PMID: 11846609

16. Pupulim LF, Vullierme M-P, Paradis V, Valla D, Terraz S, Vilgrain V. Congenital portosystemic shunts associated with liver tumours. Clin Radiol 2013; 68:e362–e369. doi: 10.1016/j.crad.2013.01.024 PMID: 23537576

17. Glatard AS, Hillaire S, d’Assignies G, Cazals-Hatem D, Plessier A, Valla DC, et al. Obliterative portal venopathy: findings at CT imaging. Radiology 2012; 263:741–750. doi: 10.1148/radiol.12111785 PMID: 22474672

18. Ding BS, Nolan DJ, Butler JM, James D, Babazadeh AO, Rosenwaks Z, et al. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 2010; 468:310–315. doi: 10.1038/nature09493 PMID: 21068842

19. Yue HY, Yin C, Hou JL, Zeng X, Chen YX, Zhong W, et al. Hepatocyte nuclear factor 4 alpha attenuates hepatic fibrosis in rats. Gut 2009; 59:236–246. doi: 10.1136/gut.2008.174904 PMID: 19671543

20. Nejak-Bowen K, Monga SP. Wnt/beta-catenin signaling in hepatic organogenesis. Organogenesis 2008; 4:92–99. PMID: 19279720

21. Abu-Amara M, Yang SY, Seifalian A, Davidson B, Fuller B. The nitric oxide pathway—evidence and mechanisms for protection against liver ischaemia reperfusion injury. Liver Int 2012; 32:531–543. doi: 10.1111/j.1478-3231.2012.02755.x PMID: 22316165

22. Nath B, Szabo G. Hypoxia and Hypoxia Inducible Factors: Diverse Roles in Liver Diseases. J Hepatol 2012; 55:622–633

23. Tivers MS, Lipscomb VJ, Scase TJ, Priestnall SL, House AK, Gates H, et al. Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Expression in Biopsy Samples of Liver from Dogs with Congenital Portosystemic Shunts. J Comp Pathol 2012; 147:55–61. doi: 10.1016/j.jcpa.2011.09.001 PMID: 21996035

24. Moreau R. VEGF-induced angiogenesis drives collateral circulation in portal hypertension. J Hepatol 2005; 43:6–8. PMID: 15893843

25. Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghen H. Angiogenesis in chronic liver disease and its complications. Liver Int. 2011; 31:146–162. doi: 10.1111/j.1478-3231.2010.02369.x PMID: 21073649

26. Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol. 2010; 53:976–980. doi: 10.1016/j.jhep.2010.07.004 PMID: 20800926

27. Inagaki Y, Okazaki I. Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 2007; 56:284–292. PMID: 17303605

28. Cohen MM Jr. TGF beta/Smad signaling system and its pathologic correlates. Am J Med Genet A 2003; 116A:1–10. PMID: 12476444

29. Bioulac-Sage P, Saric J, Boussarie L, Balabaud C. Congenital portacaval shunt in rats: liver adaptation to lack of portal vein—a light and electron microscopic study. Hepatology 1985; 5:1183–1189. PMID: 2415438

30. Zaitoun AA, Apelqvist G, Al-Mardini H, Gray T, Bengtsson F, Record CO. Quantitative studies of liver atrophy after portacaval shunt in the rat. J Surg Res 2006; 131:225–232. PMID: 16427088
31. Zipprich A, Loureiro Silva MR, D’Silva I, Groszmann J. The role of hepatic arterial flow on portal venous and hepatic venous wedged pressure in the isolated perfused CCl4-cirrhotic liver Am J Physiol Gastro-intest Liver Physiol 2008. 295: G197–G202. doi: 10.1152/ajpgi.00190.2007 PMID: 18497333

32. Kollmar O, Corsten M, Scheuer C, Vollmar B, Schilling MK, Menger MD. Portal branch ligation induces a hepatic arterial buffer response, microvascular remodeling, normoxegenation, and cell proliferation in portal blood-deprived liver tissue. Am J Physiol 2007; 292:G1534–G1542. PMID: 17347450

33. Rocheleau B, Ethier C, Houle R, Huet PM, Bilodeau M. Hepatic artery buffer response following left portal vein ligation: its role in liver tissue homeostasis. Am J Physiol 1999; 277:G1000–G1007. PMID: 10564106

34. Um S, Nishida O, Tokubayashi M, Kimura F, Takimoto Y, Yoshioka H, et al. Hemodynamic changes after ligation of a major branch of the portal vein in rats: Comparison with rats with portal vein constriction. Hepatology 1994; 19:202–209. PMID: 8276356

35. Rozga J, Jeppsson B, Bengmark S. Hepatotrophic effect of portal blood during hepatic arterial recirculation. Eur Surg Res 1986; 18:302–311. PMID: 3758135

36. Gock M, Eipel C, Linnebacher M, Klar E, Vollmar B. Impact of portal branch ligation on tissue regeneration, microcirculatory response and microarchitecture in portal blood-deprived and undeprived liver tissue. Microvasc Res 2011; 81:274–280. doi: 10.1016/j.mvr.2011.03.005 PMID: 21397614

37. Reiberger T, Angermayr B1, Schwabl P1, Rohr Udilova N, Mitterhauser M, et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol 2009; 51 865–873. doi: 10.1016/j.jhep.2009.06.024 PMID: 19726100